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Abstract: Until a few years ago cervical cancer was one of the commonest type of cancer in women worldwide.
Its incidence decreased dramatically following the implementation of the Papanicolaou (Pap) smear as a
screening procedure. The Pap smear can detect a wide range of abnormalities of the cervix from benign cellular
changes to precancerous conditions. Part of this review, will focus on this issue, specifically the abnormal
and/or possibly precancerous findings that can be found in a Pap smear result. These will be classified
according to the Bethesda system. One must emphasize here that most of these abnormalities regress on their
own and do not need specific treatment. Yet, findings like the High-grade Squamous Intraepithelial Lesion
(HSIL) have a high rate of progression to cancer and necessitate immediate management.  The other half of this
review will focus on cervical cancer in itself, a malignant and therefore invasive disease which, like all other
cancers, can be fatal if left untreated. The extent of spread of the cancer is determined by the staging system,
here described according to the International Federation of Gynecology and Obstetrics (FIGO). Staging is an
important means of evaluating the treatment plans used.
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INTRODUCTION becoming infected with HPV (Palefsky, 2002). It has also
Nearly 500, 000 women each year develop cervical response against the virus, whereas younger ones do not
cancer (Parkin et al., 1993) and a quarter of a million (Tatti, 2003). Uncircumcised men are more likely to
women die each year from it (Craus et al., 2005). Cervical harbour the virus. HPV is also associated to a certain
cancer, that is, cancer of the cervix or neck of the uterus, degree with penile cancer. 
is the second most common type of cancer in women in However, being infected with the virus does not
developed countries and the second most common cause necessarily mean that a woman will develop cervical
of death from cancer (Lowy and Schiller, 2006) following cancer. Other risk factors must be present that increase a
breast cancer. It is also the most common type of cancer woman’s chance that her infection will result in neoplastic
in women in developing countries and the most frequent changes in her cervix. These are:
female genital cancer in many states worldwide. 
Infection by sexually-transmitted, oncogenic C Low socio-economic status and/or inadequate
subtypes of Human Papillomavirus (HPV) is the main screening.
cause of cervical cancer. Human papillomavirus (HPV) the C Smoking-nicotine has been found in the cervical
DNA of which is found in 100% of histologically mucus of women who smoke (Tatti, 2003).
confirmed cervical cancers (Craus et al., 2005) is the most C Number of live births/multiple pregnancies.
common sexually transmitted virus. It is estimated that C Long-term use of oral contraceptives-these alter the
75% of sexually active adults transmit HPV at some way an HPV infection can progress (Tatti, 2003). 
instance during their life (Palefsky, 2002). C Immunosuppression, either due to drug treatment,
A woman’s sexual behavior may increase her risk of secondary to haematological malignancies or due to
becoming infected with the virus. In fact, the risk factors HIV infection (Cubie, 2007).
for acquiring HPV infection are the following: Sexual C Infection with Chlamydia trachomatis-this organism
activity at an early age, having multiple sexual partners, makes the cervix more prone to the cellular changes
having a partner who has many sex partners, having an induced by HPV (Palefsky, 2002). 
uncircumcised partner and having a partner with penile C Use of hormonal drug diethylstilbestrol (DES).
cancer (Tatti, 2003). In young women, the cervix is still C Family history of cervical cancer-this increases the
maturing and the transformation zone is vulnerable to risk of developing dysplasia (Palefsky, 2002). 
been found that older women develop an immune
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The introduction of the Papanicolaou (Pap) smear because women with ASC-H are at a considerably higher
and the treatment of Cervical Intraepithelial Neoplasia risk for developing Cervical Intraepithelial Neoplasia (CIN)
(CIN) are mainly responsible for the decrease in the 2 or 3 and of being positive for high-risk HPV DNA than
incidence of cervical cancer that has been observed over are women with ASC-US (IARC, 2005). The absence of
the last decades. Screening women aged 35-64 years high risk HPV in patients with ASC-H indicates the
every 5 years leads to an 84% reduction in cervical cancer absence of HSIL and this means that HPV-DNA testing is
incidence. If screening is done every three years, there a means to better select which patients with ASC-H
will be a higher reduction; but if screening is done more should undergo colposcopic examination (Liman et al.,
often, the incidence of cervical cancer will not decrease 2005).  In  fact,  reflex  HPV  DNA  testing  may  be used as
any further (Busuttil et al., 2006). an alternative triage method for women diagnosed with
The incidence of cervical cancer will not decrease if ASC-H  especially  for  women  older  than  30  years of
<70% of a particular population is screened (Quint et al., age (Wu et al., 2006). High-risk cases are referred for
2006). It is for this reason that cervical cancer remains the colposcopy (Manos et al., 1999). 
most frequent cancer amongst women in developing
countries. Developing countries do not have the Atypical glandular cell of undetermined significance:
resources to sustain screening programmes. Also, women The term Atypical Glandular cells of Undetermined
in developing countries lack awareness of cervical cancer Significance (AGUS) can be simply referred to Atypical
symptoms and most importantly they do not know how Glandular Cells (AGC). Although, relatively rare (found in
cervical cancer can be prevented. Adequate knowledge less than 1% of all Pap smears) it may cause diagnostic
about cervical cancer among health workers in Ibadan, for uncertainty (Mood et al., 2006) and often indicates more
example, is lacking and the Pap smear is unpopular serious problems than does ASCUS (Palefsky, 2002)
(Ayinde and Omigbodun, 2003). Screening high-risk (Table 1).  In  fact, 56% of the AGC findings are
women  in developing countries once or twice in  their associated with  cancerous  or  precancerous  conditions
lifetime  might  be an effective beginning (Adesina et al., (Scheiden et al., 2004) hence, the term AGUS is a
2003). misnomer (Disaia and Creasman, 2002). AGUS is
PRE-INVASIVE CERVICAL overactive cell changes, whilst it is diagnosed as favor
DISEASE-THE BETHESDA SYSTEM RATING neoplasia when cells indicates that a precancerous
Atypical squamous cell of undetermined significance: Moreover, women younger than 35 years of age with
The term Atypical Squamous Cell of Undetermined an AGC result have a higher frequency of histopathologic
Significance (ASCUS) (Palefsky, 2002) is sometimes findings, typically squamous lesions. On the other hand,
simply called Atypical Squamous Cell (ASC) (IARC, 2005). women with an AGC finding who are older than 50 years
As shown in (Table 1) this phrase is used when of age have more glandular lesions than do younger
cytological findings are more suspicious than benign women. Therefore, AGC represents a marker for serious
changes (Palefsky, 2002) and indicative but not diagnostic pathologic processes (Geier et al., 2001). Because of this,
of a Squamous Intraepithelial Lesion (SIL). a complete and careful evaluation (Scheiden et al., 2004)
An ASCUS finding occurs in about 5% of women and follow-up (Mood et al., 2006) is necessary. In fact, the
undergoing cytological screening (Murta et al., 2007). recommendations are colposcopy and endocervical
ASCUS indicates some cellular change that could develop curettage (Palefsky, 2002).
into dysplasia, the presence of existing dysplasia and/or Identifying AGC in pregnancy is particularly difficult.
the presence of one or more of infections like candida Some cytological changes associated with pregnancy and
infection, bacterial vaginosis or trichomonas infection. the postpartum period are benign findings that may be
Although, 68% of ASCUS diagnosed regress to normal misidentified as an adenocarcinoma. For this reason, the
(Palefsky, 2002) CIN or invasive lesions can still occur in pathologist must know if the patient is pregnant or not
women with a diagnosis of ASCUS. Therefore, immediate (Connolly and Evans, 2005).
review of the thin sections, new cytological tests or
colposcopy and rigorous follow-up should be considered Low-grade squamous intraepithelial lesion: A Low-grade
(Murta et al., 2007). Squamous Intraepithelial Lesion (LSIL) is equivalent to
ASCUS is divided into two categories: ASC-US mild  dysplasia  or CIN I. (Cervical Intraepithelial
(unsatisfactory significance) and ASC-H (cells that Neoplasia grade I). Most mild dysplasias are associated
cannot exclude HSIL). This subdivision is important with oncogenic  HPV  types  (Palefsky,  2002,  as  shown
diagnosed as favor reactive when it more likely to be
condition may already have developed (Palefsky, 2002).
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Table 1: Different classifications of cellular changes within the cervix and their relation to HPV (Palefsky, 2002)
Class system Bethesda system Dysplasia system rating Cervical intraepithelial HPV
rating (Pap smears) rating (Pap smears) (tissue biopsies) neoplasia (CIN) system rating relationship rating
0 Unsatisfactory Unsatisfactory Unsatisfactory Not enough evidence to study
1 Within normal limits Negative Negative Not directly linked to HPV
1 Benign cellular changes Negative Negative Not directly linked to HPV
2 ASC-US or AGUS favor reactive No term No term May or may not be linked to HPV
2 ASC-H or AGUS favor neoplasia No term No term May or may not be linked to HPV
3 LSIL Mild CIN 1 Directly linked to HPV
3 HSIL Moderate CIN 2 Directly linked to HPV
3 HSIL Severe CIN 3 Directly linked to HPV
4 HSIL Carcinoma in situ (CIS) CIN 3 Directly linked to HPV
5 Carcinoma Carcinoma Carcinoma Directly linked to HPV
ASC-US = Atypical Squamous Cell of Undetermined Significance; AGUS = Atypical Glandular cell of Undetermined Significance; ASC-H = Atypical
Squamous Cells; LSIL = Low-grade Squamous Intraepithelial Lesions; HSIL = High-grade Squamous Intraepithelial Lesions 
in Table 1. In fact, the cytological features that define CIN
I overlap with the cellular changes that HPV causes.
These changes include multinucleation, perinuclear halos,
nuclear atypia, irregular nuclear outlines and
hyperchromasia. These features are together referred to as
koilocytosis (IARC, 2005). 
No symptoms are usually present and the changes
are fully reversible. Yet still, some cases of mild dysplasia
are associated with low-risk types like HPV 6 or 11, in
which  case,  warts  on the cervix may be present
(Palefsky, 2002). Colposcopy and directed biopsy are
indicated in cases of repeat LSIL smears. Local excision
can be performed after diagnosis, but treatment may not
be needed because 60% of cases regress on their own
(Disaia and Creasman, 2002). 
High-grade squamous intraepithelial lesion: A High-
grade Squamous Intraepithelial Lesion (HSIL) possesses
a wide variation in its cytological appearance and usually
indicates moderate and severe dysplasia of the cervix,
both of which, but especially the latter, have a high
probability of progression to cancer (Palefsky, 2002)
(Table 1). HSIL of the moderate dysplasia type contains
cells similar to those seen in LSIL. In severe dysplasia, the
overall size of the cells is reduced, but because the cells
show minimal differentiation, the nuclear: Cytoplasmic
ratio is greatly increased (IARC, 2005). HSIL nearly always
indicate the presence of a high-risk HPV type.
Colposcopy and directed biopsy are indicated in cases of
repeat HSIL smears (Disaia and Creasman, 2002).
Treatment involves the performance of Loop
Electrosurgical Excision Procedure (LEEP), conization or
cryotherapy (Palefsky, 2002). 
CERVICAL CANCER
Type of tumour: There exist a wide variety of malignant
cervical tumours as shown in Table 2 85-90% of cervical
Table 2: Malignant  tumours  of  the  uterine cervix. Adapted from
Buckley et al. (1993)
Squamous carcinoma Well differentiated, keratinizing
Moderately well differentiated, focally keratinizing
Poorly differentiated, large cell, non-keratinizing










Mixed tumours Adenosquamous carcinoma
Glassy cell carcinoma
Adenoid cystic tumours
Small cell carcinomas Neuroendocrine tumours
Adenoid basal carcinoma







cancers  are  squamous  cell carcinomas. Most of the
other tumours, are usually adenocarcinomas arising from
the endocervical mucous-producing glandular cells.
These create what are known as barrel-shaped lesions,
large neoplasms that expand throughout the cervical
canal. Local recurrence is more common in these lesions
maybe because they are more radioresistant or due to the
bulky nature of these lesions. Neuroendocrine small cell
cervical cancers occur infrequently and have a poor
prognosis.  More  rare  cancers  include  cervical
sarcomas, cervical leimyomyomas and cervical melanomas
(Disaia and Creasman, 2002). 
Staging: The extent of cervical cancer is usually
described by the staging system shown in Table 3.
Staging   is   determined   by  clinical  examination,  that
is,   rectovaginal   examintion,   radiography,   colposcopy,
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Table 3: Staging for cervical cancer, according to the International
Federation of Gynecology and Obstetrics (IARC, 2005)
Stage Description
0 Carcinoma in situ, preinvasive carcinoma
I Invasive carcinoma, strictly confined to cervix
IA Invasive carcinoma identified microscopically 
IAI Measured invasion of stroma 3.0 mm or less in depth and 7.0 mm
or less in horizontal spread
IA2 Measured invasion of stroma >3.0 mm but mo >5.0 mm in depth
and 7.0 mm or less in horizontal spread
IB Clinically visible lesion confined to cervix or microscopic lesion
greater than stage IA2
IB1 Clinical lesions of 4.0 cm or less in size
IB2 Clinical lesions >4.0 cm in size
II Carcinoma extending beyond cervix but not to pelvic side wall;
carcinoma involves vagina but not its lower third
IIA No parametrial involvement
IIB Parametrial involvement
III Carcinoma extending onto pelvic wall; the tumour involves lower
third of vagina. All patients with hydronephrosis or non-functioning
kidney are included unless known to be the result of other causes
IIIA Involvement of lower third of vagina; no extension of pelvic
sidewall
IIIB Extension to pelvic sidewall and/of hydronephrosis or non-
functioning kidney
IV Carcinoma extends beyond true pelvis or clinically involves
mucosa of bladder or rectum.
IVA Spread of growth to adjacent organs
IVB Spread to distant organs
cystoscopy, proctosigmoidoscopy, Intravenous Pyelo-
graphy (IVP) and/or barium studies of the lower colon and
rectum. Staging is an important means of evaluating the
treatment plans used. Other factors influencing the
treatment given are the age and general health of the
patient and the presence and nature of any complicating
abnormality (Disaia and Creasman, 2002). 
MICROINVASIVE CERVICAL CARCINOMA
In 1973, the Society of Gynaecologic Oncologists
(SGO) defined a microinvasive lesion as one in which a
neoplastic epithelium invades the stroma in one or more
places to the depth of $3 mm below the base of the
epithelium and in which there is no visible lymphatic or
vascular involvement. In 1994, the International
Federation  of  Gynaecology  and  Obstetrics  (FIGO)
better defined microinvasive cervical cancer by
classifying it as stage  I (a/b) in the FIGO staging for
cervical  cancer  (Table  3).  Vascular and/or lymphatic
space    involvement    would   not   exclude   a  patient
from  this   definition.   Patients   with   FIGO   stage  Ia1
can  be  treated  with  simple  hysterectomy,  or, if
continued fertility is desired, conisation of the cervix is
performed. Therapy for stage Ia2 is by radical
hysterectomy and pelvic lymphadenectomy (Disaia and
Creasman, 2002). 
INVASIVE CERVICAL CARCINOMA
Symptoms: The first symptom of early cervical cancer is
a thin, watery, blood-tinged vaginal discharge that
frequently goes unnoticed by the patient, whilst the
classic symptom is intermittent, painless metorrhagia or
spotting only postcoitally or after douching. As the
malignancy enlarges, the bleeding episodes become
heavier and more frequent. The patient may notice this as
an increase in the amount and duration of her menstrual
flow; ultimately, the bleeding becomes continuous. 
Late symptoms include the development of pain
referred to the flank or to the leg. This is usually
secondary to the involvement of the ureters, pelvic wall or
sciatic nerve routes. Many patients complain of dysuria,
haematuria, rectal bleeding or constipation resulting from
bladder or rectal invasion. Distant metastasis and
persistent oedema of one or both lower limbs as a result
of lymphatic and venous blockage as a result of pelvic
wall disease are late manifestations of primary disease or
of recurrent disease. Massive haemorrhage and the
development of uremia with profound inanition may also
occur (Disaia and Creasman, 2002). 
Routes of spread: The main routes of spread of carcinoma
of the cervix are:
C Into the vaginal mucosa.
C Into the myometrium of the uterus.
C Into the paracervical lymphatics which travel to the
obturator, hypogastric and external iliac nodes. 
C Direct extension into adjacent structures or
parametria, which may reach the obturator fascia and
the walls of the true pelvis. The bladder and rectum
can also become involved. 
Lymph  node  involvement  in  stage  1  is  between
15-20%; in stage 2 between 25 and 40% and in stage 3, at
least 50% of the nodes are involved. The metastasis
status of pelvic lymph nodes (PLNs) seems to be a
predictive factor of survival. The presence of HPV DNA
and other biological markers in PLN may indicate a sub-
clinical early metastasis, but it may be associated to an
active immune reaction (Landro et al., 2008).
Treatment
Surgical management: Radical hysterectomy was
introduced in 1944 following dissatisfaction with
radiotherapy. It involves the removal of the uterus, the
upper two-thirds of the vagina, the uterosacral and
uterovesical  ligaments,  all  of  the parametrium on each
side  and  and  pelvic  node  dissection encompassing  the
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obturator, ureteral, hypogastriic and iliac lymph node RECURRENT AND ADVANCED 
chains. Metastasis to the ovaries is rare and hence these
structures can be preserved. 
The major complication following this technique is
postoperative bladder dysfunction. This arises due to
direct injury to the sensory and motor nerve supply of the
detrusor muscle of the bladder and is usually manifested
as a loss of the sense of urgency to void and an inability
to empty the bladder completely. For this reason, long
periods of constant bladder drainage may be necessary
post-operatively and patients may need to be taught
intermittent self-catheterization. Another complication is
pulmonary embolism. The operative period is the most
dangerous period for the formation of a thrombus in the
leg or pelvic veins. For this reason the pelvic veins should
be carefully dissected for minimal thrombus formation in
these structures. Other complications, all of which are
preventable, include the development of ureteral fistulas
and lymphocysts, pelvic infection and haemorrhage.
Whilst antibiotics prevent pelvic infection, they
contribute to fistula formation. Finally, recurrence is
expected in 10-20% of patients treated with radical
hysterectomy and bilateral lymphadenectomy (Disaia and
Creasman, 2002). 
Radiotherapy and adjuvant chemotherapy: Radiation
therapy is successful if the cancer cell has a greater
sensitivity to a normal cell to ionizing radiation; if the
normal tissue has a greater ability to recuperate after
irradiation and if the patient is in a reasonably good
physical condition. The maximal effect of ionizing
radiation on cancer is obtained in the presence of a good
and intact circulation and adequate tissue oxygenation.
Consideration must be given to the tolerance of the
normal tissues of the pelvis, which are likely to receive
high doses during the course of treatment of cervical
malignancy. A general principle of radiotherapy states
that the normal tissue tolerance of any organ is inversely
related to the volume of the organ receiving irradiation
(Disaia and Creasman, 2002). 
Five large randomized controlled trials showed that
survival of patients with cervical cancer is improved if
adjuvant chemotherapy is used in combination with
radiation. Primary radiotherapy is delivered as a
combination of external-beam teletherapy and
brachytherapy and given with concurrent cisplatin-based
chemotherapy (Gray, 2008). The addition of weekly
cisplatin  to radiotherapy is recommended for patients
with  high-risk  early stage cervical cancer who undergo
a radical  hysterectomy  and  pelvic  lymphadenectomy
(Liu et al., 2000). This technique improves long-term PFS
and OS (Rose et al., 2007) and gives the best results if the
dose and delivery time of the radiation are carefully
controlled (Pearcey et al., 2002).
CERVICAL CARCINOMA
Definition: Approximately, 35% of patients with invasive
cervical cancer will have recurrent or persistent disease
after therapy. Recurrence after surgery is defined as
evidence of a tumour mass after all gross tumour has been
removed and the margins of the specimen were free of
disease. Persistent disease after surgery is defined as
persistence of gross tumour in the operative field or local
recurrence of tumour within one year of initial surgery. A
new cancer of the cervix would be a lesion that occurs
locally at least ten years after primary therapy. 
The definition of persistent disease after radiation
therapy is the evidence of a portion of the tumour that
was clinically present before treatment or else, the
development of a new demonstrable tumour in the pelvis
within the treatment period. The definition of recurrence
after radiation therapy is a regrowth of the tumour in the
pelvis or distally, which is noted after complete healing of
the cervix and vagina (Disaia and Creasman, 2002). 
Locations of recurrence: After radical hysterectomy,
about one fourth of recurrences occur locally in the upper
part of the vagina or the area previously occupied by the
cervix. Twenty seven percent of recurrences occur in the
cervix, uterus or upper vagina; 6% in the lower two-thirds
of the vagina; 43% in the parametrial area, including the
pelvic wall; 16% distant and 8% unknown (Disaia and
Creasman, 2002). Skin metastasis is a late manifestation in
cervical cancer patients and indicates widespread
metastasis of the disease (Chen et al., 2007).
Signs and symptoms: These are:
C Unexplained weight loss.
C Leg oedema-due to progressive lymphatic
obstruction, occlusion of the iliofemoral vein system
or both.
C Pain radiating to the upper thigh or to the buttock.
Sometimes, it may be pain in the groin or a deep-
seated central pelvic pain.
C Vaginal bleeding and a watery smelly discharge-
suggest a central recurrence.
C Ureteral obstruction.
C Enlargement of supraclavicular lymph nodes
especially on the left side.
C Cough, haemoptysis and chest pain due to
pulmonary metastasis (Disaia and Creasman, 2002). 
Management: Radical hysterectomy is the therapy for
small recurrent cervical carcinoma following radiation. In
cases  of  bone metastasis, external irradiation in moderate
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doses can relieve the pain. Radiation is also used in cases For those women who unfortunately have been
of recurrence after radical hysterectomy has been
performed. Patients with bilateral ureteral obstruction
should be considered for urinary diversion followed by
radiation. Pelvic exenteration-removal of many pelvic
viscera-can be performed in cases of recurrent pelvic
cancer;  however,  only  a  few patients are suitable for
this  operation  and  can  lead to fatal complications
(Disaia and Creasman, 2002). Anterior pelvic exenteration
with the formation of an ileal conduit allows radiotherapy
to be used to treat recurrent disease (Barrington et al.,
1997).
Various studies have been conducted to establish the
benefits of chemotherapy in advanced and recurrent
cervical cancer. Response to combined chemotherapy
varies from 16-69% depending on the size of the lesion
and previous radiotherapy (Alberts et al., 1998). Using
cisplatin and 5-flourouracil, dose-cumulative neuro-
toxocity develops as a side-effect (Chiara et al., 1988).
Nephrotoxicity, mucositis and diarrhoea are the main
potential toxicities from this type of treatment.
Nephrotoxicity can be prevented by prehydration and by
reducing the duration of infusion (Kish et al., 1985).
Toxicity can also be improved by the use of growth
stimulating factor (Ghaemmaghami et al., 2003). 
Recent data suggests that topotecan, a semisynthetic
camptothecin which exerts its cytotoxic effect through
inhibition of DNA topoisomerase I (Randall-Whitis and
Monk, 2007), when used concurrently with cisplatin, may
be the new standard of care for the management of
recurrent  or  advanced  cervical  cancer.  Although,
single-agent cisplatin-based chemoradiotherapy is the
standard  of  care  for high-risk or locally advanced
cervical cancer, topotecan, when used concurrently with
cisplatin and/or radiation therapy, produces high
objective response rates, improved overall survival and
progression-free survival (Ackermann et al., 2007). 
CONCLUSION
Cervical cancer is a preventable disease. Its aetiology
and associated risk factors have been well documented in
the literature. Its relation to HPV is unquestionable. 
Until a few years ago, most emphasis as to how
prevent cervical cancer was based on screening tests. The
efficacy of the smear test, which was and is still used to
detect precancerous changes in the cervix, has been
improved by the implementation of liquid-based cervical
cytology. Also, HPV DNA testing is now used as an
adjunct to cervical cytology for women aged 30 years and
older. For maximum benefit, screening programmes in all
countries must be organized and not done haphazardly. 
diagnosed with invasive cervical cancer, or who will be
diagnosed with this disease in the future, it is important
that correct evaluation of the lesion/s and appropriate
treatment be given. The lesion should be defined
according to the International Federation of Gynaecology
and Obstetrics (FIGO) staging system. Prior to treatment,
histopathological evaluation of the lesion and appropriate
tests on the patient must be performed, what is known as
pre-treatment evaluation. Treatment in itself, on the other
hand, must be based on several factors, most importantly
the size of the lesion. Follow-up must be done on patients
who have been treated for invasive cervical cancer,
because they remain at risk of recurrence. As regards
recurrent cervical cancer, the treatment chosen is usually
based on the localization of the site of recurrence and of
the extent of the disease. 
Emphasis should be placed as to how decrease
cervical cancer incidence in developing countries. Here,
cervical cancer is still the most frequent cancer amongst
women and a major cause of death. In the literature one
finds lots of studies carried out about the female situation
in these regions. It is in these countries, which are not few
in number, that many women are encountering the
disease, are not treated for it and die from it. It is also in
these countries that women are not aware of how cervical
cancer can be prevented because they are not educated
about it. Even health care workers living in these places
lack adequate knowledge about the disease. 
Developing countries lack adequate resources and
finances to sustain regular screening programmes. They
also lack specialists involved in the interpretation of
results. In order to organize an effective screening
programme in developing countries, there need to be
adequate financial resources, the infrastructure must be
developed and the necessary people must be trained
(Adesina et al., 2003). 
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